Results 31 to 40 of about 123,453 (307)

Covid-19-Associated Coagulopathy: Biomarkers of Thrombin Generation and Fibrinolysis Leading the Outcome

Journal of Clinical Medicine, 2020
Background: Coronavirus Disease 2019 (COVID-19)-associated coagulopathy is characterized by a prothrombotic state not yet comprehensively studied. We investigated the coagulation pattern of patients with COVID-19 acute respiratory distress syndrome (ARDS)
M. Ranucci, C. Sitzia, E. Baryshnikova, Umberto Di Dedda, R. Cardani, F. Martelli, M. C. Corsi Romanelli   +6 more
semanticscholar   +1 more source

Coagulation and anticoagulation in idiopathic pulmonary fibrosis [PDF]

, 2015
Idiopathic pulmonary fibrosis (IPF) is an incurable, progressive interstitial lung disease with a prognosis that is worse than that of many cancers. Epidemiological studies have demonstrated a link between IPF and thrombotic vascular events.
Crooks, Michael G., Hart, Simon P.
core   +3 more sources

Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins

Haematologica, 2009
Background Thrombin is the main activator of the fibrinolysis inhibitor TAFI (thrombin activatable fibrinolysis inhibitor) and heightened clotting activation is believed to impair fibrinolysis through the increase of thrombin activatable fibrinolysis ...
Fabrizio Semeraro, Concetta T. Ammollo, Nicola Semeraro, Mario Colucci   +3 more
doaj   +1 more source

Fibrin Breakdown Assay

Bio-Protocol, 2020
Fibrinolysis is an integral part of the matrix remodeling process that contributes to tissue repair. Fibrin clots are broken down during fibrinolysis in a controlled process.
Jiayue Ling, Connor Blair, George Baillie   +2 more
doaj   +1 more source

Fibrinolysis and COVID‐19: A plasmin paradox

Journal of Thrombosis and Haemostasis, 2020
The COVID‐19 pandemic has provided many challenges in the field of thrombosis and hemostasis. Among these is a novel form of coagulopathy that includes exceptionally high levels of D‐dimer.
R. Medcalf, C. Keragala, P. Myles
semanticscholar   +1 more source

Fibrinolysis and Inflammation in Venous Thrombus Resolution

Frontiers in Immunology, 2019
Clinical observations and accumulating laboratory evidence support a complex interplay between coagulation, inflammation, innate immunity and fibrinolysis in venous thromboembolism (VTE).
S. Mukhopadhyay, Tierra A. Johnson, Nadire Duru, Marguerite S Buzza, Nisha R Pawar, R. Sarkar, T. Antalis   +6 more
semanticscholar   +1 more source

Relationship Between Severity of Fibrinolysis Based on Rotational Thromboelastometry and Conventional Fibrinolysis Markers

Clinical and Applied Thrombosis/Hemostasis, 2020
The association between severity of fibrinolysis, ascertained by rotational thromboelastometry to diagnose hyperfibrinolysis in patients with out-of-hospital cardiac arrest (OHCA), and conventional fibrinolysis markers (ie, tissue-plasminogen activator ...
Tomoyo Saito MD, PhD, Mineji Hayakawa MD, PhD, Yoshinori Honma MD, Asumi Mizugaki MD, Tomonao Yoshida MD, Kenichi Katabami MD, Takeshi Wada MD, PhD, Kunihiko Maekawa MD   +7 more
doaj   +1 more source

What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies

Blood Coagulation and Fibrinolysis, 2019
&NA; Intravenous tranexamic acid (TXA) reduces death because of bleeding in patients with trauma and postpartum haemorrhage. However, in some settings intravenous injection is not feasible.
R. Picetti, H. Shakur-Still, R. Medcalf, J. Standing, I. Roberts   +4 more
semanticscholar   +1 more source

Evaluation of coagulation activation after Rhinovirus infection in patients with asthma and healthy control subjects: an observational study [PDF]

, 2014
Background Asthma exacerbations are frequently triggered by rhinovirus infections. Both asthma and respiratory tract infection can activate haemostasis. Therefore we hypothesized that experimental rhinovirus-16 infection and asthmatic airway inflammation
Bel, EHD, De Pol, MAV, Johnston, SL, Kamphuisen, PW, Lutter, R, Majoor, CJ, Meijers, JCM, Molenkamp, R, Nieuwland, R, Sterk, PJ, Van der Poll, T, Van der Sluijs, KF, Wolthers, KC   +12 more
core   +4 more sources

Angiographic outcomes in STEMI patients receiving fibrinolysis with guideline directed optimal antithrombotic therapy

Indian Heart Journal, 2021
STEMI is a major public health problem requiring timely reperfusion. Fibrinolysis remains prevalent reperfusion strategy where timely primary percutaneous coronary intervention (PCI) cannot be performed.
Shazia Durdana, Mohammad Azharuddin Malik, Asif Hasan, M.U. Rabbani   +3 more
doaj   +1 more source